Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale
Back to Newsroom
Mentioned in this Article

Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale

Monday, June 29, 2020 9:00 AM
Share this article now
Topic:
Company Update

SEATTLE, WA / ACCESSWIRE / June 29, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, announced today that it has collected in full the $750,000 placed into an escrow account for working capital adjustments. This collection relates to the Company's sale of its Hemophilia B therapy, IXINITY®, to Medexus Pharmaceuticals.

The sale transaction, completed in February 2020, included an upfront payment to Aptevo of $30 million. In addition, Aptevo is eligible to receive potential milestone payments totaling up to $11 million from Medexus related to the certain regulatory and commercial activities. Also, for up to fifteen years, Aptevo will receive deferred payments on future U.S. and Canadian net sales of IXINITY calculated at a low to mid-single digit percentage of net sales.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603 were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer. For more information, please visit www.aptevotherapeutics.com

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo's outlook, financial performance or financial condition, estimated cash burn, Aptevo's technology and related pipeline, collaboration and partnership opportunities, milestones, and any other statements containing the words "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates," "will" and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 25, 2020 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement.

Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
+1 206-859-6628
[email protected]

SOURCE: Aptevo Therapeutics

Aptevo Therapeutics
Exchange:
Ticker:
NASDAQ
APVO
$7.69
0.65%
Back to Newsroom
Copyright 2020 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: